WntResearch AB (publ)
556738-7864
Press release 2015-12-21
WntResearch: Swedish site will participate in the Foxy-5 phase 1b
study
WntResearch today announces that the Department of Oncology and the Clinical
Trial Unit (Phase I), R&D Centre, Skåne University Hospital Lund have agreed to
participate as a site in the clinical phase 1b study with Foxy-5. The phase 1b study
will be initiated as soon as the study application has been approved (see press
release 2015-12-14).
Nils Brünner, CEO: “We are very happy to extend the number of clinical sites for the
upcoming phase 1b study with a Swedish site. This ought to result in a more efficient
recruitment of patients into the study.”
For additional information please contact:
Nils Brünner, CEO
E-mail: [email protected]
Telephone: + 45 2614 4708
About WntResearch
WntResearch AB is a public company on the AktieTorget in Sweden. WntResearch develops
the anti-cancer compound Foxy-5 to be used to combat the metastatic process of cancer.
WntResearch has one drug candidate in clinical phase 1 – Foxy-5 – as well as one candidate
drug in preclinical development – Box-5. The Company is currently focusing mainly on the
development of Foxy-5.
